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Changes in renal function are one of the most common manifestations of severe illness. There is a clinical need to intervene early 
with proven treatments in patients with potentially deleterious changes in renal function. Unfortunately progress has been hin-
dered by poor definitions of renal dysfunction and a lack of early biomarkers of renal injury. In recent years, the definitional prob-
lem has been addressed with the establishment of a new well-defined diagnostic entity, acute kidney injury (AKI), which encom-
passes the wide spectrum of kidney dysfunction, together with clearer definition and sub-classification of the cardio-renal syn-
dromes. From the laboratory have emerged new biomarkers which allow early detection of AKI, including neutrophil gelatinase-
associated lipocalin (NGAL) and cystatin C. This review describes the new concepts of AKI and the cardio-renal syndromes as well 
as novel biomarkers which allow early detection of AKI. Panels of AKI biomarker tests are likely to revolutionise the diagnosis and 
management of critically ill patients in the coming years. Earlier diagnosis and intervention should significantly reduce the morbid-
ity and mortality associated with acute kidney damage.
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INTRODUCTION
Changes in renal function are one of the most common 
manifestations of severe illness. Their importance is re-
flected in the routine physiological and biochemical moni-
toring of kidney function via urine output measures and 
blood laboratory measurements in critically ill patients. De-
spite improvements in health outcomes in many areas in re-
cent years, mortality and morbidity rates associated with 
acute renal dysfunction remain high. There is a clinical need 
to intervene early with proven treatments in patients with 
potentially deleterious changes in renal function. Unfortu-
nately progress has been hindered by poor definitions of re-
nal dysfunction and a lack of early biomarkers of renal in-
jury. In recent years, the definitional problem has been ad-
dressed with the establishment of a new well-defined diag-
nostic entity, acute kidney injury (AKI), which encompasses 
the wide spectrum of kidney dysfunction, together with 
clearer definition and sub-classification of the cardio-renal 
syndromes. From the laboratory have emerged new bio-
markers which allow early detection of AKI, including neu-
trophil gelatinase-associated lipocalin (NGAL) and cystatin 
C. These new approaches offer increased hope that early ef-
fective treatments for AKI can improve the clinical out-
comes of seriously ill patients. This review will describe the 
new concepts of AKI and the cardio-renal syndromes as 
well as novel biomarkers which allow early detection of AKI.
NEW DISEASE CONCEPTS
1. Acute kidney injury
The term “acute renal failure” was first used in 1951 by 
Homer Smith with reference to acute renal failure related to 
traumatic injury [1]. It has since entered the mainstream 
medical lexicon with over 18,000 PubMed references by the 
end of 2010. Despite its popularity, the term has suffered 
from a lack of clear definition which limited discussion in 
the area and has complicated comparisons of epidemiologi-
cal and therapeutic studies. A variety of different prevalence Hawkins R  •  New Biomarkers of AKI and the CRS
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figures have been reported, reflecting more than 35 differ-
ent definitions of acute renal failure found in the literature 
[2]. This has led to a wide range of mortality rates from 27% 
to 60% associated with acute renal failure [3-6]. Generally 
the definitions have been based on absolute or relative con-
centration or changes in concentration of serum creatinine. 
Some have used extremely complicated criteria based on 
different increases in serum creatinine concentration from 
different baseline values [7, 8].
In an effort to improve consensus and allow the develop-
ment of evidence-based guidelines for the management of 
acute kidney dysfunction, the Acute Dialysis Quality Initia-
tive (ADQI) suggested a graded definition called the RIFLE 
criteria in 2004 [9, 10]. The RIFLE criteria uses three levels 
of injury (Risk, Injury and Failure) based on either serum 
creatinine concentration, glomerular filtration rate (GFR) 
or urine output and two levels of outcome (Loss and End-
stage Renal Disease [ESRD]) based on the need for renal 
replacement therapy (RRT) and the time period. The differ-
ent levels are shown in Table 1. 
The patient should be classified at the least favourable 
level resulting from assessment of the different variables 
(serum creatinine concentration, GFR and urine output). 
The diagnostic descriptor used should be “RIFLE-R”, “RI-
FLE-I”, etc. as appropriate. It has suggested that a subscript 
“o” should be added (e.g. RIFLE-Fo) if the classification re-
sults from urine output assessment and “c” to denote the 
presence of pre-existing renal disease [11].
The RIFLE criteria have been adopted by the nephrology 
community but some limitations have been highlighted in 
recent years. The choice of matching serum creatinine and 
urine output measures at each level was not evidence based 
and the predictive power of the creatinine and urine output 
criteria is not equivalent. One study has found the serum 
creatinine criteria of the classification seems to be a better 
predictor of mortality than urine output [12]. Use of the RI-
FLE criteria is limited in patients who present with AKI but 
without a baseline creatinine concentration. Back-calcula-
tion of a baseline creatinine concentration using the 4-pa-
rameter MDRD equation assuming a baseline GFR of 75 
mL/min/1.73 m
2 has been suggested to overcome this prob-
lem but further work to support this approach is needed [9].
In 2007 the Acute Kidney Injury Network (AKIN) sug-
gested a modified set of criteria based on the RIFLE ap-
proach [13-15]. The term acute kidney “injury” as opposed 
to “failure” was used to reflect coverage of the full range of 
acute renal dysfunction and has been adopted as a Medical 
Subject Heading (MeSH) by the U.S. National Library of 
Medicine in 2011. AKIN proposed 3 separate stages for AKI 
which correspond to the RIFLE criteria; Stage 1 (Risk), Stage 
2 (Injury) and Stage 3 (Failure).  RIFLE levels Loss and Fail-
ure are considered outcomes rather than stages. The AKIN 
approach is shown in Table 1.
The diagnostic criteria should be used only following ade-
quate resuscitation when applicable [15]. This is to exclude 
changes in creatinine concentration or urine output second-
ary to transient easily reversible fluid depletion. Exclusion of 
urinary tract obstruction is also suggested if oliguria is the 
only diagnostic criterion met. As a consequence, a patient 
with urinary tract obstruction and oliguria alone will not 
meet the AKI criteria while another with urinary tract ob-
struction and raised creatinine concentration will do so. 
Both the fluid replacement and urinary tract obstruction re-
strictions may exclude some of the traditional pre-renal and 
Table 1. Acute kidney injury classification systems
Stage Creatinine criteria Urine output criteria
RIFLE system
  Risk 1.5-2 fold increase in serum creatinine concentration or 25% decrease in GFR Urine output <0.5 mL/kg/hr for 6 hr
  Injury 2-3 fold increase in serum creatinine concentration or 50% decrease in GFR Urine output <0.5 mL/kg/hr for 12 hr
  Failure >3 fold increase in serum creatinine concentration or 75% decrease in GFR or serum creatinine  
concentration >4 mg/dL (350 μmol/L) with an acute elevation of >0.5 mg/dL (44μmol/L)
Urine output <0.3 mL/kg/hr for 24 hr or 
anuria for 12 hr
  Loss Complete loss of renal function (e.g. requirement for RRT) for more than 4 weeks
  End-stage kidney disease Complete loss of renal function (e.g. requirement for RRT) for more than 3 months
  AKIN system
    1 1.5-2 fold increase in serum creatinine concentration or increase in serum creatinine concentration 
≥0.3 mg/dL (27 μmol/L)
Urine output <0.5 mL/kg/hr for 6 hr
    2 2-3 fold increase in serum creatinine concentration  Urine output <0.5 mL/kg/hr for 12 hr
    3 >3 fold increase in serum creatinine concentration or serum creatinine concentration ≥4 mg/dL (354 
μmol/L) with an acute increase >0.5 mg/dL (44 μmol/L)
Urine output <0.3 mL/kg/hr for 24 hr or 
anuria for 12 hr
RRT, renal replacement therapy.74     www.kjlm.org
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post-renal cases of acute renal failure from the AKI category. 
However, the main focus in developing the criteria was to 
allow for epidemiological and outcome comparisons be-
tween different sites and treatments, rather than for individ-
ual patient diagnosis and management. Hence these changes 
will result in arguably smaller but cleaner, more homoge-
neous groups that will simplify inter-study comparisons.
A cornerstone of both the RIFLE and AKIN criteria is the 
measurement of serum creatinine concentration as a marker 
of renal function. The shortcomings of serum creatinine 
concentration in reflecting GFR are well known. Serum cre-
atinine is only useful in patients with stable renal function – 
in acute renal dysfunction, the GFR may be reduced but the 
serum creatinine concentration may be normal or low as 
there has been insufficient time for creatinine to accumulate 
[16]. Although creatinine freely filters across the glomerular 
membrane and is neither absorbed nor metabolised by the 
kidney, 10-40% of urinary creatinine is secreted by the prox-
imal tubule into the urine [17]. As GFR falls in chronic kid-
ney disease, the increase in serum creatinine can be blunted 
by increasing creatinine secretion [17-21]. Nephrotic syn-
drome can also lead to increased creatinine secretion and a 
reduction in serum creatinine concentration [22]. Creati-
nine concentrations may be lowered in advanced renal dis-
ease where intestinal bacterial overgrowth leads to increased 
bacterial creatininase activity and enhanced extrarenal cre-
atinine elimination [23].
Creatinine production varies between individuals based 
on dietary intake and body habitus. There are sex and race 
differences in serum creatinine concentration reflecting dif-
ferences in muscle mass and thus differences in the rates of 
creatinine production from muscle creatine. Men have 
higher serum creatinine concentrations than women and 
blacks have higher values than whites, who in turn have 
higher values than Malays, Indians and Chinese [24, 25]. 
Creatinine concentrations measured using the alkaline pic-
rate method are prone to drug (e.g. cefoxitin, flucytosine) or 
metabolite (e.g. ketone) interference [26-30]. Drugs such as 
trimethoprim and cimetidine may decrease tubular creati-
nine secretion leading to elevation in serum creatinine con-
centration by up to 0.4-0.5 mg/dL (35-44 μmol/L) [31-33]. 
Creatinine is also removed by dialysis, limiting the useful-
ness of creatinine measurement once dialysis has begun.
In addition to serum creatinine concentration’s limita-
tions in reflecting changes in GFR, compensatory hypertro-
phy and hyperfiltration of unaffected glomeruli in cases of 
progressive glomerular loss may mean levels of both creati-
nine and GFR may not necessarily reflect the underlying 
renal injury [18, 19, 34]. Proteinuria, abnormalities of urine 
sediment, and systemic hypertension may be the only signs 
of such silent damage.
2. Cardio-renal syndrome
Another clinical concept whose definition has been re-
fined in recent years is the cardio-renal syndrome (CRS). 
There is a close association between renal and cardiac func-
tion in both acute and chronic diseases. Cardiovascular dis-
ease causes over 50% of deaths in patients with renal failure 
while poor renal function increases mortality in patients 
with heart failure [35-37]. The term “cardio-renal syndrome” 
had been loosely used in the past to describe the relationship 
between renal and cardiac function but it was not until 2004 
that the National Heart, Lung, and Blood Institute defined 
CRS as a condition in which therapy to relieve congestive 
symptoms of heart failure is limited by a decline in renal 
function as manifested by a reduction in glomerular filtra-
tion rate. Although this definition suggests a one-way effect 
of renal on cardiac function, further work has shown the in-
teractions to work in both directions and in a variety of clin-
ical conditions [38]. In 2008 the ADQI suggested the use of 
CRS to identify a disorder of the heart and kidneys whereby 
acute or chronic dysfunction in one organ may induce acute 
or chronic dysfunction in the other organ [39]. The ADQI 
report had similar goals to the RIFLE and AKIN initiatives 
in encouraging comparison between epidemiological and 
interventional studies as well as the development of diagnos-
tic tools for the prevention and management of the different 
syndromes.
Five different subtypes of syndrome were identified:
Acute cardio-renal syndrome (type 1): acute worsening 
of heart function leading to kidney injury and/or dysfunc-
tion. Up to 40% of patients with acute decompensated heart 
failure develop AKI and fall into this category [40, 41]. AKI 
was defined as the secondary event using RIFLE-AKIN cri-
teria.
Chronic cardio-renal syndrome (type 2): chronic abnor-
malities in heart function leading to kidney injury and/or 
dysfunction. Up to 63% of hospitalised patients with conges-
tive heart failure fall into this category [42, 43]. Renal dys-
function was defined as the secondary event using KDOQI 
criteria [42].
Acute reno-cardiac syndrome (type 3): acute worsening 
of kidney function (AKI) leading to heart injury and/or 
dysfunction. AKI was defined as the primary event using 
RIFLE-AKIN criteria.
Chronic reno-cardiac syndrome (type 4): chronic kidney 
disease leading to heart injury, disease, and/or dysfunction. Hawkins R  •  New Biomarkers of AKI and the CRS
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Excess cardiovascular deaths associated with increasing re-
nal dysfunction have been estimated at over 50% [44]. Re-
nal dysfunction was defined as the secondary event using 
KDOQI criteria [42].
Secondary CRS (type 5): systemic conditions (e.g. sepsis, 
systemic lupus erythematosus, diabetes mellitus, amyloido-
sis, or other chronic inflammatory conditions) leading to si-
multaneous injury and/or dysfunction of heart and kidney. 
AKI was defined as one of the possible secondary events us-
ing RIFLE-AKIN criteria.
As can be seen, identification of AKI is key to the defini-
tions of types 1, 3 and 5 CRS. Adoption of the RIFLE-AKIN 
criteria enables common dialogue between the cardiology 
and nephrology communities but the reliance of the RIFLE 
and AKIN systems on serum creatinine measurement and 
its limitations discussed earlier remains. There is a need for 
new specific biomarkers that identify kidney injury early 
and that can replace serum creatinine in both the definition 
of AKI for epidemiological and study purposes as well as in 
guiding individual patient management.
 
BIOMARKERS OF ACUTE KIDNEY INJURY
In recent years, a number of novel biomarkers have been 
developed which promise earlier and more specific detec-
tion of acute kidney injury. Following their initial identifica-
tion and preliminary work in animal and human AKI mod-
els, they are becoming available from a number of vendors 
for use in the clinical laboratory.
1. Neutrophil gelatinase-associated lipocalin
NGAL is arguably the most promising emerging bioma-
rker for detection of AKI. It is composed of 8 β-strands that 
form a β-barrel enclosing a calyx which binds and trans-
ports low-molecular-weight substances [45]. In humans, 
NGAL is a 25 kDa 178 amino acid chain which is predomi-
nantly in a monomeric form. It is expressed by neutrophils 
and other epithelial cells including those in the proximal 
collecting tubule [46]. It appears to have a role in binding 
siderophores (small iron-carrying molecules) [47]. Studies 
in mouse models of renal ischemia reperfusion showed 
NGAL production to be highly up-regulated at an early 
stage and NGAL was detected in the urine within 2 hr fol-
lowing ischemia [48]. It has also been shown to be a marker 
of cisplatin nephrotoxicity in an animal model [49]. The 
physiological role of NGAL in this setting may be to de-
crease injury by reducing apoptosis and increasing the nor-
mal proliferation of kidney tubule cells. NGAL may also 
enhance delivery of iron and cause up-regulation of heme 
oxygenase-1, further protecting kidney tubule cells [48, 50-
53]. There is the intriguing possibility of using NGAL as a 
renoprotective agent in acute ischemic renal injury. In a 
murine model of renal ischemia-reperfusion injury, intra-
venous administration of purified recombinant NGAL ad-
ministered before, during, or after ischemia resulted in 
marked amelioration of the morphologic and functional 
consequences with a reduction in the number of apoptotic 
tubule cells and an increase in proliferating proximal tubule 
cells after ischemic injury [51].
Many clinical studies have demonstrated the ability of 
NGAL to allow early identification of AKI. A variety of clini-
cal settings have been examined, including cardiac surgery 
[54-59], contrast procedures [60, 61], intensive care units 
[62-64] and the emergency department [65]. A representa-
tive study examined the performance of NGAL as an early 
biomarker for ischemic renal injury after cardiopulmonary 
bypass in 71 children undergoing cardiopulmonary bypass. 
Serial urine and blood samples were analysed by western 
blots and ELISA for NGAL expression. The primary out-
come measure was acute renal injury, defined as a 50% in-
crease in serum creatinine from baseline. 20 children (28%) 
developed acute renal injury, but diagnosis with serum cre-
atinine was only possible 1-3 days after cardiopulmonary 
bypass. Urinary NGAL rose from a mean of 1.6 μg/L at 
baseline to 147 μg/L 2 hr after cardiopulmonary bypass, and 
the amount in the serum increased from a mean of 3.2 μg/L 
at baseline to 61 μg/L 2 hr after the procedure [59]. A recent 
systematic review and meta-analysis of the diagnostic and 
prognostic value of NGAL in AKI examined data from 19 
studies and 8 countries involving 2,538 patients, of whom 
19.2% developed AKI [66]. Overall, the area under the re-
ceiver operating curve (AUC) of NGAL to predict AKI was 
0.815 (cardiac surgery patients: 0.775; critically ill patients: 
0.728; after contrast infusion: 0.894). The diagnostic accu-
racy of blood NGAL (AUC 0.775) was similar to that of 
urine NGAL (AUC 0.837). NGAL had better predictive 
value in children (AUC 0.930) compared with adults (AUC 
0.782). It was useful in predicting both renal replacement 
therapy (AUC 0.782) and in-hospital mortality (AUC 0.706).
NGAL measurement has now been commercialised and 
can be performed in both blood (Triage Meterpro System, 
Alere International Sàrl, Morges Switzerland) and urine 
samples (Abbott Architect, Abbott Laboratories, Abbott 
Park, Illinois, USA). Both urine and blood samples have 
their advantages and shortcomings. Blood NGAL measure-
ments are invasive and may potentially reflect the effect of 
extra-renal disease on NGAL concentrations. However 
samples are readily available and the measurement can be 76     www.kjlm.org
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performed rapidly on whole blood or plasma (15-20 min) 
on a point-of-care device. Urine sampling is non-invasive 
and there are less potentially interfering proteins present 
than in blood specimens. However disadvantages include 
the lack of available specimen in oliguric patients, the effect 
of over- or under-hydration and diuretic treatment on mea-
sured urinary NGAL concentrations and a longer analytical 
time on a laboratory-based analyser. This choice in sample 
type and platform allows the flexibility to offer the test in a 
variety of different clinical settings.
There are many scenarios where NGAL measurement 
could be useful, including critical illness, sepsis, oliguria, 
contrast procedures, cardiopulmonary bypass and poly-
trauma [56, 59-63, 67-69]. NGAL may be helpful in disease 
monitoring in other renal diseases, lupus nephritis, IgA ne-
phropathy and polycystic kidney disease [70-73]. It could 
also be useful in non-renal conditions such as brain tumors, 
inflammatory bowel disease and pre-eclampsia [74-76]. 
NGAL appears to be an exciting marker of AKI but more 
work needs to be done to confirm its utility in routine clini-
cal practice and to fine-tune the choice of appropriate cut-
offs for different clinical settings and populations.
2. Cystatin C
Cystatin C is a 13.3 kDa low molecular weight member 
of the cystatin superfamily of cysteine protease inhibitors 
which is synthesised by all nucleated cells at a constant pro-
duction rate. It is freely filtered at the glomerulus and is not 
reabsorbed, although it is metabolised by the renal tubules, 
which limits the utility of urinary measurement. Although 
it was purported to be unaffected by gender, age or muscle 
mass, more recent work has shown higher concentrations 
in men, those of greater height and weight, higher lean 
body mass and increasing age [77-79]. Studies over 20 yr 
have generally shown cystatin C to be a better predictor of 
GFR than creatinine. A meta-analysis of 49 studies covering 
4,492 individuals showed cystatin C to have a greater AUC 
than creatinine (0.926 vs 0.837) in predicting GFR [80]. 
Cystatin C measurement allows earlier detection of AKI 
than serum creatinine measurement [81]. In 85 patients at 
high risk to develop AKI using RIFLE criteria, serum creat-
inine and cystatin C was measured daily. In the 44 patients 
who developed AKI, the increase of cystatin C (>50% over 
baseline) preceded that of creatinine by 1.5 days. A more 
recent study has shown cystatin C to rise significantly at 12 
hr after pediatric cardiopulmonary bypass in patients who 
subsequently developed AKI [82]. Compared to NGAL, 
cystatin C rises later in AKI, with several studies in adults 
administered contrast showing an early rise in both urine (4 
hr) and plasma (2 hr) NGAL compared to a later increase 
in cystatin C (8-24 hr) [83-85]. Cystatin C suffers from a 
lack of assay standardisation, which limits the generalisabil-
ity of many study findings.
3. Other biomarkers
Kidney injury molecule-1 (KIM-1) is a transmembrane 
glycoprotein whose production is up-regulated in the proxi-
mal tubule in AKI [86-88]. It can be measured in urine and 
can help identify the etiology of AKI. Higher concentra-
tions are seen in ischemic AKI compared to other forms of 
AKI and chronic kidney disease [89]. Urinary concentra-
tions rise 6-12 hr following cardiopulmonary bypass in pa-
tients who subsequently develop AKI in a timeframe simi-
lar to that of NGAL [90].
Interleukin-18 (IL-18) is a mediator of inflammation 
which is induced in the proximal tubule and can be mea-
sured in urine as an early marker of AKI. Concentrations 
rise 6 hr after cardiopulmonary bypass in patients subse-
quently diagnosed with AKI [91]. It is more specific for 
ischemic insult and is unaffected by chronic kidney disease, 
urinary tract infections or nephrotoxins [92]. However the 
literature on its utility is mixed with a study of 100 patients 
undergoing cardiac surgery suggesting it was not valuable 
in identifying patients who develop AKI after cardiac sur-
gery but was a nonspecific marker of cardiopulmonary by-
pass-associated systemic inflammation [93].
Other potential biomarkers include urinary tubular en-
zymes which are released from proximal tubular epithelial 
cells within 12 hr of AKI. They include N-acetyl-β-glucosa-
minidase (NAG), proximal renal tubular epithelial antigen, 
α-glutathione S-transferase, π-glutathione S-transferase, 
γ-glutamyltranspeptidase, alanine aminopeptidase, lactate 
dehydrogenase, and alkaline phosphatase. Urinary low-mo-
lecular-weight proteins such as α1-microglobulin, β2-mic-
roglobulin, retinol binding protein, adenosine deaminase 
binding protein are produced at different sites in the body, 
filtered at the glomerulus, and reabsorbed at the proximal 
tubule with no secretion. Although some of these analytes 
appear promising, clinical evaluations are limited and there 
is little published data on their specificity for AKI [94, 95].
4. Acute kidney injury panels
Of the many new biomarkers available, NGAL appears to 
be the most promising but it is likely to be most useful when 
combined with other markers such as cystatin C or KIM-1 
to form an “AKI panel” [96-99]. Several studies have exam-
ined the use of such biomarkers in combination [88, 100, 
101]. In a study of 100 adult cardiac surgical patients mea-Hawkins R  •  New Biomarkers of AKI and the CRS
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suring NGAL and cystatin C as well as urea and creatinine, 
the new biomarkers were superior to the conventional mea-
sures in predicting AKI. Blood NGAL and cystatin C were 
independent predictors of AKI [100]. Another study mea-
sured KIM-1, NAG and NGAL in 90 adults undergoing 
cardiac surgery. The AUCs for KIM-1 to predict AKI im-
mediately and 3 hr after operation were 0.68 and 0.65; 0.61 
and 0.63 for NAG; and 0.59 and 0.65 for NGAL, respec-
tively. Combining the three biomarkers enhanced the sensi-
tivity of early detection of postoperative AKI compared 
with individual biomarkers: the AUCs for the three bio-
markers combined were 0.75 and 0.78. The performance of 
combining biomarkers was even better among 16 early 
postoperative AKI patients with AUCs of 0.80 and 0.84, re-
spectively [88].
CONCLUSION
The recent development of the RIFLE and AKIN criteria 
for AKI and the sub-classifications of CRS have prompted 
increased research and clinical interest in earlier and more 
specific markers of AKI. These tests are now becoming 
available in the clinical sphere and promise to change the 
paradigm for AKI diagnosis and management. Identifica-
tion of AKI will no longer rely on functional markers such 
as serum creatinine concentration with its temporal and 
analytical shortcomings. The availability of panels of tests 
such as NGAL, cystatin C and KIM-1 are likely to revolu-
tionise the diagnosis and management of critically ill pa-
tients in the coming years. Earlier diagnosis and interven-
tion should significantly reduce the morbidity and mortal-
ity associated with acute kidney damage.
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